National Institute for health and clinical excellence (NICE) will recommend from Roche-AVASTIN (bevacizumab) when used in combination with taxane as a useful, cost-effective treatment option for people with breast cancer that has spread. Health care cost storage envelope body which offer the drug "limited and existing treatments compared with uncertain benefits for patients."
Roche has calculated that the average total cost of treating a patient with AVASTIN plus chemotherapy exceeds $52,000, according to Reuters.
"Unfortunately, we have not received to show no evidence of the manufacturer, bevacizumab can significantly extend a patient life or, more importantly, offer a better quality of life than existing treatments," NICE Managing Director Andrew Dillon says in a statement. "Although the data show to be seemed that the drug can slow down the growth and spread of cancer, varies the size of this effect between studies." "Furthermore, it was extremely clear that the benefits in terms of slowing tumor growth in overall survival benefits that is something really important for the patients translated."
He adds that the body is consciously the FDA and EMEA review license of the drug for the treatment of metastatic breast cancer are. "If either... changes announce your licensing decision affecting our advice to the NHS, we change it accordingly," he warns.
The decision is no big surprise as Reuters notes, since AVASTIN has already been rejected for colorectal cancer. But the negative comments are mark uncertainty about its use elsewhere.
Monday's Bloomberg reported AVASTIN could not survive in a study of patients with brain cancer diagnosed to extend. Patients given living brain cancer drug Avastin with radiation therapy and Merck's Temodar 19.6 months, depending on according to the results of the study in the journal of Clinical Oncology. This figure compares life 21.1 months in patients with the extension only the other two treatments in another study given.
-NICE statement to get
-Schauen you are Reuters reporting
Reading you the Bloomberg report
Related articles:
Roche-AVASTIN rejected by NICE for colorectal cancer
AVASTIN, Tamiflu Roche depress sales by 7 %
Europe connects breast cancer check AVASTIN
Roche-AVASTIN receives FDA Aufschub--now
No comments:
Post a Comment